The local medical sector is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for treating obesity. This treatment suggests https://auresortwear.com/2026/06/10/retatrutide-australia-my-deep-dive-into-weight-loss-treatments/